A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2006
10/18/2006	EP1711186A1 Slow release steroid composition
10/18/2006	EP1711185A1 Combination of a cdk inhibitor and cs-682 or a metabolite thereof
10/18/2006	EP1711184A1 (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
10/18/2006	EP1711183A2 Muscarinic acetylcholine receptor antagonists
10/18/2006	EP1711182A1 Oral cyclodextrin complexes of antituberculosis drugs
10/18/2006	EP1711181A1 Quinoline derivatives and use thereof as mycobacterial inhibitors
10/18/2006	EP1711180A1 Thiazolylimidazole derivatives and their use as inhibitors of microsomal triglyceride transfer protein
10/18/2006	EP1711179A2 Calcium, potassium, zinc, lithium and aluminium salts of pantoprazole and (s)-pantoprazole
10/18/2006	EP1711178A1 Compositions substantially free of galactomannan containing piperacillin and tazobactam
10/18/2006	EP1711177A1 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS
10/18/2006	EP1711176A1 Immunomodulatory alkaloids
10/18/2006	EP1711175A1 Diurea derivatives
10/18/2006	EP1711174A1 Adjuvant compositions
10/18/2006	EP1711173A2 Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
10/18/2006	EP1711171A2 Vitamin e for facilitating the synchronization of circadian rhythm
10/18/2006	EP1711170A1 Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid
10/18/2006	EP1711169A1 Extended release coated microtablets of venlafaxine hydrochloride
10/18/2006	EP1711167A1 Multiparticulate o-desmethylvenlafaxine salts and uses thereof
10/18/2006	EP1711166A1 Stable amorphous forms of montelukast sodium
10/18/2006	EP1711164A2 Method of treating acute rhinosinusitis
10/18/2006	EP1711163A2 Dispersions prepared by use of self-stabilizing agents
10/18/2006	EP1711162A1 Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method
10/18/2006	EP1711161A2 Methods of preventing and treating sars using low ph respiratory tract compositions
10/18/2006	EP1711160A2 Flat system for using in the oral cavity
10/18/2006	EP1711158A1 Otic detergent composition for animals, with edta and chlorexhidine
10/18/2006	EP1711157A1 Composition for treating a dermatological inflammatory response and method of preparation thereof
10/18/2006	EP1711124A1 Long-term delivery formulations and methods of use thereof
10/18/2006	EP1711070A1 Nutritional composiition for improving skin condition and preventing skin diseases
10/18/2006	EP1711056A1 Antimicrobial compositions comprising polymeric stabilizers
10/18/2006	EP1711054A1 Method and compositions for treatment of painful disorders
10/18/2006	EP1626730A4 Method, apparatus, and composition for treating acne
10/18/2006	EP1572683B1 Novel piperidine derivatives as modulators of chemokine receptor ccr5
10/18/2006	EP1567146B1 Iontophoretic delivery of rotigotine for the treatment of parkinson's disease
10/18/2006	EP1539152A4 Development of muscle mass in a mammal
10/18/2006	EP1513418B1 Use of pullulan as a slowly digested carbohydrate
10/18/2006	EP1481063B1 Delta 6-desaturases from primulaceae, expressing plants and pufa-containing oils
10/18/2006	EP1437358B1 Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
10/18/2006	EP1423112B1 A combination of quetiapine and zolmitriptan
10/18/2006	EP1414830B1 Tumour inhibiting lanthane compounds
10/18/2006	EP1414829B1 Tumour inhibiting cerium compounds
10/18/2006	EP1392686B1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials
10/18/2006	EP1389236B1 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof
10/18/2006	EP1358332B1 A serpin in bifidobacteria
10/18/2006	EP1345932B1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
10/18/2006	EP1339714B1 Novel sulfonamide-substituted pyrazolopyridine derivatives
10/18/2006	EP1283828B1 Novel polymorph v of torasemide
10/18/2006	EP1265604B1 Process for recovering statin compounds from a fermentation broth
10/18/2006	EP1239850B1 Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-n-methyl-ethylammonium chloride as anti-inflammatory agents
10/18/2006	EP1214068B1 Ophthalmic fluid
10/18/2006	EP1212070B1 Plant extract mixtures (cissus, vernonia, brillantaisia) and their uses
10/18/2006	EP1208196B1 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
10/18/2006	EP1189897B1 Isoflavone metabolites
10/18/2006	EP1183383B1 Siv-based packaging-deficient vectors
10/18/2006	EP1180039B1 Composition for the treatment of a neurological disorder
10/18/2006	EP1128815B1 Process for preparing oral calcium compositions
10/18/2006	EP1107957B1 Pyrimidine compounds
10/18/2006	EP1084710B1 Adenosine a1 antagonists for male sterility
10/18/2006	EP1072266B8 Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
10/18/2006	EP1070713B1 Quinolonecarboxylic acid derivatives or salts thereof
10/18/2006	EP1062362A4 Levo-monosaccharide in a nucleoside analog for use as an antiretroviral agent
10/18/2006	EP1019500B1 Ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
10/18/2006	EP1004667B1 Cell cycle-regulating proteins
10/18/2006	EP0994961B1 Homoserine lactones biofilm regulating compounds and their methods of use
10/18/2006	EP0948511B1 Chemical synthesis of nucleosides analogs and their incorporation into polynucleotides
10/18/2006	EP0931063B1 N-substituted indol-3-glyoxylamid with antiasthmatic, antiallergic and immunosuppressive/immunomodulating effect
10/18/2006	EP0914165B1 Steroids as neurochemical stimulators of the vno to alleviate symptoms of pms
10/18/2006	CN1849336A Chimeric gabab receptor
10/18/2006	CN1849330A Specific glucocorticosteroid compound having anti-inflammatory activity
10/18/2006	CN1849328A Novel 14 and 15 membered-ring compounds
10/18/2006	CN1849325A Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting prot ein kinases
10/18/2006	CN1849323A Thienopyrroles as antiviral agents
10/18/2006	CN1849320A Process for the preparation of renzapride and intermediates thereof
10/18/2006	CN1849319A Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands
10/18/2006	CN1849318A Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
10/18/2006	CN1849317A Crystal of heterocyclic compound
10/18/2006	CN1849316A 7-(4-substituted 3- cyclopropylaminomethyl-1- pyrrolidinyl) Q uinolonecarboxylic acid derivative
10/18/2006	CN1849315A Novel amides useful for treating pain
10/18/2006	CN1849313A 抗生素化合物 Antibiotic compounds
10/18/2006	CN1849312A Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics
10/18/2006	CN1849311A Acetone solvate of dimethoxy docetaxel and its process of preparation
10/18/2006	CN1849310A Thiazole derivatives as cannabinoid receptor modulators
10/18/2006	CN1849309A Pyridyl derivatives and their use as therapeutic agents
10/18/2006	CN1849308A Thiophenylaminoimidazolines
10/18/2006	CN1849307A Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
10/18/2006	CN1849306A Matrix metalloproteinase inhibitors
10/18/2006	CN1849303A Novel heteroaryl derivative
10/18/2006	CN1849302A 1, 3-disubstituted azetidine derivatives for use as CCR-3 receptor antagonists in the treatment of inflammatory and allergic diseases
10/18/2006	CN1849301A Substituted arylthiourea derivatives useful as inhibitors of viral replication
10/18/2006	CN1849287A Reduced coenzyme Q10 crystal with excellent stability and composition containing said reduced coenzyme Q10 crystal
10/18/2006	CN1849153A Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
10/18/2006	CN1849142A 2'-branched nucleosides and flaviviridae mutation
10/18/2006	CN1849140A Bitterness-masking particulate jelly beverage
10/18/2006	CN1849135A Methods for treating interleukin-6-related diseases
10/18/2006	CN1849131A Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor
10/18/2006	CN1849128A Selectively inhibiting estrogen production and providing estrogenic effects in the human body
10/18/2006	CN1849127A Use of parapheny for maldehyde-O-beta-D-allose pyranoside for treating neurogenic pain
10/18/2006	CN1849126A 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
10/18/2006	CN1849125A Therapeutic agent for ageing macular degeneration
10/18/2006	CN1849124A Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeabi
10/18/2006	CN1849123A Oral itraconazole composition which is not affected by ingested food and process for preparing same

1 ... 4047 4048 4049 4050 4051 4052 4053 4054 4055 4056 4057 4058 4059 4060 4061 4062 4063 4064 4065 4066 4067 ... 7860